The pharmacoepidemiology of COPD: Recent advances and methodological discussion

European Respiratory Journal, Supplement

Volumn 22, Issue 43, 2003, Pages

  Burney, P ^a   Suissa, S ^b   Soriano, J B ^c,d   Vollmer, W M ^e   Viegi, G ^f   Sullivan, S D ^g   Fabbri, L M ^h   Sin, D D ⁱ   Ernst, P ^j   Coultas, D ^k   Bourbeau, J ^j   Mapel, D W ^l   Weiss, K ^m   McLaughlin, T ⁿ   Price, D ^o   Sturkenboom, M C J M ^p   Taylor, R ^q   Hagan, G W ^r  

^a Dept of Public Health Services ^*  (United Kingdom)

^b ROYAL VICTORIA HOSPITAL   (Canada)

^c Worldwide Epidemiology   (United Kingdom)

^d LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^e KAISER PERMANENTE   (United States)

^f INSTITUTE OF CLINICAL PHYSIOLOGY   (Italy)

^g UNIVERSITY OF WASHINGTON   (United States)

^h UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

ⁱ UNIVERSITY OF ALBERTA   (Canada)

^j MCGILL UNIVERSITY   (Canada)

^k UNIVERSITY OF FLORIDA HEALTH SCIENCE CENTER   (United States)

^l LOVELACE CLINIC FOUNDATION   (United States)

^m NORTHWESTERN UNIVERSITY   (United States)

ⁿ Outcomes Research   (United States)

^o UNIVERSITY OF ABERDEEN   (United Kingdom)

^p ERASMUS MEDICAL CENTER   (Netherlands)

^q UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^r GLAXOSMITHKLINE   (United Kingdom)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ADRENERGIC RECEPTOR STIMULATING AGENT; ALCOHOL; ANTIBIOTIC AGENT; ANTIHISTAMINIC AGENT; BAMBUTEROL; BECLOMETASONE; BECLOMETASONE DIPROPIONATE; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BRONCHODILATING AGENT; BUDESONIDE; BUSPIRONE; CHOLINERGIC RECEPTOR BLOCKING AGENT; CIGARETTE SMOKE; CORTICOSTEROID; FENOTEROL; FLUNISOLIDE; FLUTICASONE PROPIONATE; FORMOTEROL; IPRATROPIUM BROMIDE; LONG ACTING DRUG; NICOTINE; OXYGEN; PLACEBO; SALMETEROL; TERBUTALINE; THEOPHYLLINE DERIVATIVE; TIOTROPIUM BROMIDE; TRIAMCINOLONE; UNINDEXED DRUG; XANTHINE DERIVATIVE;

ANTIBIOTIC THERAPY; ANTIINFLAMMATORY ACTIVITY; ASTHMA; CHRONIC OBSTRUCTIVE LUNG DISEASE; CIGARETTE SMOKING; CLINICAL PRACTICE; CLINICAL RESEARCH; CLINICAL TRIAL; CONFERENCE PAPER; CORTICOSTEROID THERAPY; COST EFFECTIVENESS ANALYSIS; COST OF ILLNESS; DISEASE CONTROL; DISEASE EXACERBATION; DISEASE SEVERITY; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG MEGADOSE; ECONOMIC EVALUATION; FORCED EXPIRATORY VOLUME; HEALTH CARE COST; HEALTH CARE POLICY; HIGH RISK POPULATION; HUMAN; LONG TERM CARE; LOW DRUG DOSE; LUNG FUNCTION TEST; MAINTENANCE THERAPY; MORBIDITY; MORTALITY; OUTCOMES RESEARCH; OXYGEN THERAPY; PHARMACOEPIDEMIOLOGY; PRACTICE GUIDELINE; PRESCRIPTION; PREVALENCE; PRIORITY JOURNAL; PRODUCTIVITY; QUALITY OF LIFE; RISK FACTOR; SMOKING CESSATION; SPIROMETRY;

EID: 0141891408     PISSN: 09041850     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (168)

1. National Heart, Lung and Blood Institute. Morbidity & mortality: chartbook on cardiovascular, lung, and blood diseases. www.nhlbi.nih.gov/nhlbi/seiin/other/cht-book/htm. Bethesda, US Dept of Health and Human Services, Public Health Service, National Institutes of Health, 1998.
2. Centers for Disease Control and Prevention. Trends in ischemic heart disease mortality - United States, 1980-1988. MMWR 1992; 41: 548-556.
3. Murray CJL, Lopez AD. Evidence-based health policy - lessons from the Global Burden of Disease Study. Science, 1996; 274: 740-743.
4. Murray CJL, Lopez AD, eds. The Global Burden of Disease: A Comprehensive Assessment of Mortality and Disability from Diseases, Injuries, and Risk Factors in 1990 and Projected to 2020. Cambridge, Harvard University Press, 1996.
5. Mannino DM, Homa DM, Akinbami LJ, Ford ES, Redd SC. Chronic obstructive pulmonary disease surveillance - United States, 1971-2000. Morb Mortal Wkly Rep Surveill Summ 2002; 51: 1-16.
6. US Surgeon General. The Health Consequences of Smoking: Chronic Obstructive Pulmonary Disease. Publication No. 84-50205. Washington DC, US Dept of Health and Human Services, 1984.
7. Mannino DM, Gagnon RC, Petty TL, Lydick E. Obstructive lung disease and low lung function in adults in the United States: data from the National Health and Nutrition Examination Survey, 1988-1994. Arch Int Med 2000; 160: 1683-1689.
8. National Center for Health Statistics. Plan and operation of the Third National Health and Nutrition Examination Survey. 1988-1994. Publication PHS 94-1308. Washington DC, US Dept of Health and Human Services, 1996.
9. World Health Organization. World Health Report 1999. http://www.who.int/whr/1999/en/report.htm. Geneva, World Health Organization, 1999.
10. World Bank. Curbing the Epidemic: Governments and the Economics of Tobacco Control. http://www1.worldbank.org/ tobacco/reports.htm. 1999.
11. Administration on Aging. http://www.aoa.gov/aoa/stats/ AgePop2050.html Accessed March 2003.
12. National Heart, Lung and Blood Institute/World Health Organization Workshop Report. Global Initiative for Chronic Obstructive Lung Disease: global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. National Institutes of Health Publication No. 2701. Washington DC, US Dept of Health and Human Services, Public Health Service, National Institutes of Health, National Heart, Lung and Blood Institute, 2001. www.goldcopd.com. 2003.
13. Celli BR, Halbert RJ, Isonaka S, Schau B. Population impact of different definitions of airway obstruction. Eur Respir J 2003; 22: 268-273.
14. Hardie JA, Buist AS, Vollmer WM, Ellingsen I, Bakke PS, Mørkve O. Risk of over-diagnosis of COPD in asymptomatic elderly never-smokers. Eur Respir J 2002; 20: 1117-1122.
15. National Center for Health Statistics. Current estimates from the National Health Interview Survey, United States, 1995. Publication No. 96-1527. Washington DC, Dept of Health and Human Services, Public Health Service, Vital and Health Statistics, 1995.
16. Hnizdo E, Sullivan PA, Bang KM, Wagner G. Association between chronic obstructive pulmonary disease and employment by industry and occupation in the US population: a study of data from the Third National Health and Nutrition Examination Survey. Am J Epidemiol 2002; 156: 738-746.
17. Siafakas NM, Vermeire P, Pride NB, et on behalf of the Task Force. Optimal assessment and management of chronic obstructive pulmonary disease (COPD). Eur Respir J 1995; 8: 1398-1420.
18. Fabbri LM, Romagnoli M, Corbetta L, et al. Differences in airway inflammation in patients with fixed airflow obstruction due to asthma or chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2003; 167: 418-424.
19. American Thoracic Society. Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1995; 152: S77-S121.
20. World Health Organization. Manual of the International Statistical Classification of Diseases, Injuries and Causes of Death. Volume I. Ninth revision. Geneva, World Health Organization, 1977.
21. World Health Organization. International Statistical classification of Diseases and Related Health Problems. Tenth revision. Geneva, World Health Organization, 1992.
22. Murray CJL, Lopez AD. Alternative projections of mortality and disability by cause 1990-2020. Lancet 1997; 349: 1498-1504.
23. Gulsvik A. Mortality in and prevalence of chronic obstructive pulmonary disease in different parts of Europe. Monaldi Arch Chest Dis 1999; 54: 160-162.
24. Hurd SS. International efforts directed at attacking the problem of COPD. Chest 2000; 117: 336s-338s.
25. Pride NB, Soriano JB. Chronic obstructive pulmonary disease in the United Kingdom: trends in mortality, morbidity, and smoking. Curr Opin Pulm Med 2002; 8: 95-101.
26. Dati Istituto Superiore di Sanità. La mortalità per causa in Italia: 1980-1998. www.mortalita.iss.it
27. Camilli AE, Robbins DR, Lebowitz MD. Death certificate reporting of confirmed airways obstructive disease. Am J Epidemiol 1991; 133: 795-800.
28. lzumi T. Chronic obstructive pulmonary disease in Japan. Curr Opin Pulm Med 2002; 8: 102-105.
29. Vestbo J, Prescott E, Lange P, Schnohr P, Jensen G. Vital prognosis after hospitalization for COPD: a study of a random population sample. Respir Med 1998; 92: 772-776.
30. Prescott E, Lange P, Vestbo J. Chronic mucus hypersecretion in COPD and death from pulmonary infection. Eur Respir J 1995; 8: 1333-1338.
31. Italian National Statistics Agency. Indagine multiscopo sulle famiglie "Condizioni di salute della popolazione". 1999-2000.
32. Dati del Ministero della Salute. Ricoveri Ospedalieri-Anno 2000. www.ministerosalute.it
33. Feenstra TL, van Genugten ML, Hoogenveen RT, Wouters EF, Rutten-van Molken MP. The impact of aging and smoking on the future burden of chronic obstructive pulmonary disease: a model analysis in the Netherlands. Am J Respir Crit Care Med 2001; 164: 590-596.
34. Viegi G, Pedreschi M, Baldacci S, et al. Prevalence rates of respiratory symptoms and diseases in general population samples of North and Central Italy. Int J Tuberc Lung Dis 1999; 3: 1034-1042.
35. CIBA Foundation Guest Symposium. Terminology, definitions and classification of chronic pulmonary emphysema and related conditions. Thorax 1959; 14: 286-299.
36. Viegi G, Paoletti P, Carrozzi L, et al. Prevalence rates of respiratory symptoms in Italian general population samples, exposed to different levels of air pollution. Environ Health Perspect 1991; 94: 95-99.
37. Lundback B, Nystrom L, Rosenhall L, Stjernberg N. Obstructive lung disease in northern Sweden: respiratory symptoms assessed in a postal survey. Eur Respir J 1991; 4: 257-266.
38. Stang P, Lydick E, Silberman C, Kempel A, Keating ET. The prevalence of COPD: using smoking rates to estimate disease frequency in the general population. Chest 2000; 117: 354s-359s.
39. Lindstrom M, Jonsson E, Larsson K, Lundback B. Under-diagnosis of chronic obstructive pulmonary disease in Northern Sweden. Int J Tuberc Lung Dis 2002; 6: 76-84.
40. Pallasaho P, Lundback B, Meren M, et al. Prevalence and risk factors for asthma and chronic bronchitis in the capitals Helsinki, Stockholm, and Tallinn. Respir Med 2002; 96: 759-769.
41. Huchon GJ, Vergnenegre A, Neukirch F, Brami G, Roche N, Preux PM. Chronic bronchitis among French adults: high prevalence and underdiagnosis. Eur Respir J 2002; 20: 806-812.
42. Viegi G, Pedreschi M, Pistelli F, et al. Prevalence of airway obstruction in a general population sample. European Respiratory Society vs American Thoracic Society definition. Chest 2000; 117: 339s-345s.
43. Pauwels RA, Buist AS, Calverley PM, Jenkins CR, Hurd SS. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. National Heart, Lung and Blood Institute/World Health Organization Global Initiative for Chronic Obstructive Pulmonary Disease (GOLD) Workshop summary. Am J Respir Crit Care Med 2001; 163: 1256-1276.
44. American Thoracic Society. Evaluation of impairment/ disability secondary to respiratory disorders. American Thoracic Society. Am Rev Respir Dis 1986; 133: 1205-1209.
45. Vestbo J, Lange P. Can GOLD Stage 0 provide information of prognostic value in chronic obstructive pulmonary disease? Am J Respir Crit Care Med 2002; 166: 329-332.
46. van den Boom G, van Schayck CP, van Mollen MP, et al. Active detection of chronic obstructive pulmonary disease and asthma in the general population. Results and economic consequences of the DIMCA program. Am J Respir Crit Care Med 1998; 158: 1730-1738.
47. Zielinski J, Bednarek M. Know the Age of Your Lung Study Group: Early detection of COPD in a high-risk population using spirometric screening. Chest 2001; 119: 731-736.
48. Czajkowska-Malinowska M, Nowinski A, Gorecka D, Zielinski J. Effects of spirometric screening in the community on smoking cessation. Pneumonol Alergol Pol 2001; 69: 524-529.
49. Cerveri I, Accordini S, Verlato G, et al. European Community Respiratory Health Survey (ECRHS) Study Group. Variations in the prevalence across countries of chronic bronchitis and smoking habits in young adults. Eur Respir J 2001; 18: 85-92.
50. Rennard S, Decramer M, Calverley PM, et al. Impact of COPD in North America and Europe in 2000: subjects' perspective of Confronting COPD International Survey. Eur Respir J 2002; 20: 799-805.
51. Vestbo J, Prescott E, Lange P. Association of chronic mucus hypersecretion with FEV1 decline and chronic obstructive pulmonary disease morbidity. Copenhagen City Heart Study Group. Am J Respir Crit Care Med 1996; 153: 1530-1535.
52. Prescott E, Lange P, Vestbo J. Socioeconomic status, lung function and admission to hospital for COPD: results from the Copenhagen City Heart Study. Eur Respir J 1999; 13: 1109-1114.
53. Dahl M, Tybjaerg-Hansen A, Vestbo J, Lange P, Nordestgaard BG. Elevated plasma fibrinogen associated with reduced pulmonary function and increased risk of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2001; 164: 1008-1111.
54. Dahl M, Tybjaerg-Hansen A, Lange P, Vestbo J, Nordestgaard BG. Change in lung function and morbidity from chronic obstructive pulmonary disease in alpha1-antitrypsin MZ heterozygotes: A longitudinal study of the general population. Ann Intern Med 2002; 136: 270-279.
55. Prescott E, Almdal T, Mikkelsen KL, Tofteng CL, Vestbo J, Lange P. Prognostic value of weight change in chronic obstructive pulmonary disease: results from the Copenhagen City Heart Study. Eur Respir J 2002; 20: 539-544.
56. Brogger J, Bakke P, Eide GE, Gulsvik A. Comparison of telephone and postal survey modes on respiratory symptoms and risk factors. Am J Epidemiol 2002; 155: 572-576.
57. Welle I, Bakke PS, Eide GE, Fagerhol MK, Omenaas E, Gulsvik A. Increased circulating levels of alpha1-antitrypsin and calprotectin are associated with reduced gas diffusion in the lungs. Eur Respir J 2001; 17: 1105-1111.
58. Humerfelt S, Gulsvik A, Skjaerven R, et al. Decline in FEV1 and airflow limitation related to occupational exposures in men of an urban community. Eur Respir J 1993; 6: 1095-1103.
59. Sunyer J. Urban air pollution and chronic obstructive pulmonary disease: a review. Eur Respir J 2001; 17: 1024-1033.
60. van den Boom G, Rutten-van Molken MP, Folgering H, van Weel C, van Schayck CP. The economic effects of screening for obstructive airway disease: an economic analysis of the DIMCA program. Prev Med 2000; 30: 302-308.
61. Rutten van-Molken MP, Feenstra TL. The burden of asthma and chronic obstructive pulmonary disease: data from the Netherlands. Pharmacoeconomics 2001; 19: Suppl. 2, 1-6.
62. Dal Negro R, Berto P, Tognella S, Quareni L. Global Outcomes in Lung Disease Study Group. Cost-of-illness of lung disease in the TriVeneto Region, Italy: the GOLD Study. Monaldi Arch Chest Dis 2002; 57: 3-9.
63. Andersson F, Borg S, Jansson SA, et al. The costs of exacerbations in chronic obstructive pulmonary disease (COPD). Respir Med 2002; 96: 700-708.
64. Anto JM, Vermeire P, Vestbo J, Sunyer J. Epidemiology of chronic obstructive pulmonary disease. Eur Respir J 2001; 17: 982-994.
65. Viegi G, Scognamiglio A, Baldacci S, Pistelli F, Carrozzi L. Epidemiology of chronic obstructive pulmonary disease (COPD). Respiration 2001; 68: 4-19.
66. Drummond MF, Jefferson TO. Guidelines for authors and peer reviewers of economic submissions to the BMJ. The BMJ Economic Evaluation Working Party. BMJ 1996; 313: 275-283.
67. Siegel JE, Torrance GW, Russell LB, et al. Guidelines for pharmacoeconomic studies. Recommendations from the panel on cost-effectiveness in health and medicine, Panel on Cost-Effectiveness in Health and Medicine. Pharmacoeconomics 1997; 11: 159-168.
68. Siegel JE, Weinstein MC, Russell LB, Gold MR. Recommendations for reporting cost-effectiveness analyses. Panel on Cost-Effectiveness in Health and Medicine. JAMA 1996; 276: 1339-1341.
69. Birch S, Gafni A. On being NICE in the UK: guidelines for technology appraisal for the NHS in England and Wales. Health Econ 2002; 11: 185-191.
70. Garber AM, Phelps CE. Economic foundations of cost-effectiveness analysis. J Health Econ 1997; 16: 1-31.
71. Rice DP. Estimating the costs of illness. Am J Public Health 1967; 68: 424-440.
72. Rice DP. Estimating the cost of illness. Health Economics Series 6. Publication no. 947.6. Washington DC, US Government Printing Office, 1966.
73. Koopmanschap MA, van Ineveld BM. Towards a new approach for estimating indirect costs of disease. Soc Sci Med 1992; 34: 1005-1010.
74. Koopmanschap MA, Rutten FF. The impact of indirect costs on outcomes of health care programs. Health Econ 1994; 3: 385-393.
75. Koopmanschap MA, Rutten FF, van Ineveld BM, et al. The friction cost method for measuring indirect costs of disease. J Health Econ 1995; 14: 171-189.
76. Rothermich EA, Pathak DS. Productivity-cost controversies in cost-effectiveness analysis: review and research agenda. Clin Ther 1999; 21: 255-267.
77. Hutubessy RC, van Tulder MW, Vondeling H, Bouter LM. Indirect costs of back pain in the Netherlands: a comparison of the human capital method with the friction cost method. Pain 1999; 80: 201-207.
78. Johannesson M, Karlsson G. The friction cost method: a comment. J Health Econ 1997; 16: 249-255.
79. Koopmanschap MA, Rutten FF. A practical guide for calculating indirect costs of disease. Pharmacoeconomics 1996; 10: 460-466.
80. Goeree R, O'Brien BJ, Blackhouse G, Agro K, Goering P. The valuation of productivity costs due to premature mortality: a comparison of the human-capital and friction-cost methods for schizophrenia. Can J Psychiatry 1999; 44: 455-463.
81. Sullivan SD, Ramsey SD, Lee TA. The economic burden of COPD. Chest 2000; 117: Suppl. 2, 5S-9S.
82. Faulkner MA, Hilleman DE. The economic impact of chronic obstructive pulmonary disease. Expert Opin Pharmacother 2002; 3: 219-228.
83. Ruchlin HS, Dasbach EJ. An economic overview of chronic obstructive pulmonary disease. Pharmacoeconomics 2001; 19: 623-642.
84. Strassels SA, Smith DH, Sullivan SD, Mahajan PS. The costs of treating COPD in the United States. Chest 2001; 119: 344-352.
85. Ward MM, Javitz HS, Smith WM, Bakst A. Direct medical cost of chronic obstructive pulmonary disease in the USA. Respir Med 2000; 94: 1123-1129.
86. Jacobson L, Hertzman P, Lofdahl CG, Skoogh BE, Lindgren B. The economic impact of asthma and chronic obstructive pulmonary disease (COPD) in Sweden in 1980 and 1991. Respir Med 2000; 94: 247-255.
87. Buck DJ, Richmond RL, Mendelsohn CP. Cost-effectiveness analysis of a family physician delivered smoking cessation program. Prev Med 2000; 31: 641-648.
88. Curry SJ, Grothaus LC, McAfee T, et al. Use and cost effectiveness of smoking-cessation services under four insurance plans in a health maintenance organization. N Engl J Med 1998; 339: 673-679.
89. Meenan RT, Stevens VJ, Hornbrook MC, et al. Cost-effectiveness of a hospital-based smoking cessation intervention. Med Care 1998; 36: 670-678.
90. Fiscella K, Franks P. Cost-effectiveness of the transdermal nicotine patch as an adjunct to physicians' smoking cessation counseling. JAMA 1996; 275: 1247-1251.
91. Lennox AS, Osman LM, Reiter E, et al. Cost effectiveness of computer tailored and non-tailored smoking cessation letters in general practice: randomised controlled trial. BMJ 2001; 322: 1396.
92. Wasley MA, McNagny SE, Phillips VL, Ahluwalia JS. The cost-effectiveness of the nicotine transdermal patch for smoking cessation. Prev Med 1997; 26: 264-270.
93. Weiss SJ, Jurs S, Lesage JP, Iverson DC. A cost-benefit analysis of a smoking cessation program. Eval Program Plann 1984; 7: 337-346.
94. Molken MP, van Doorslaer EK, Rutten FF. Economic appraisal of asthma and COPD care: a literature review 1980-1991. Soc Sci Med 1992; 35: 161-175.
95. Rennard SI. New therapeutic drugs in the management of chronic obstructive pulmonary disease. Curr Opin Pulm Med 2002; 8: 106-111.
96. Mahler DA, Donohue JF, Barbee RA, et al. Efficacy of salmeterol xinafoate in the treatment of COPD. Chest 1999; 115: 957-965.
97. Ramirez-Venegas A, Ward J, Lentine T, Mahler DA. Salmeterol reduces dyspnea and improves lung function in patients with COPD. Chest 1997; 112: 336-340.
98. Dahl R, Greefhorst LA, Nowak D, et al. Inhaled formoterol dry powder reduces ipratropium bromide in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2001; 164: 778-784.
99. Rossi A, Kristufek P, Levine BE, et al. Comparison of the efficacy, tolerability, and safety of formoterol dry powder and oral, slow-release theophylline in the treatment of COPD. Chest 2002; 121: 1058-1069.
100. Wadbo M, Lofdahl CG, Larsson K, et al. Effects of formoterol and ipratropium bromide in COPD: a 3-month placebo-controlled study. Eur Respir J 2002; 20: 1138-1146.
101. Hansel TT, Barnes PJ. Tiotropium bromide: a novel once-daily anticholinergic bronchodilator for the treatment of COPD. Drugs Today 2002; 38: 585-600.
102. Casaburi R, Mahler DA, Jones PW, et al. A long-term evaluation of once-daily inhaled tiotropium in chronic obstructive pulmonary disease. Eur Respir J 2002; 19: 217-224.
103. D'Urzo AD, De Salvo MC, Ramirez-Rivera A, et al. In patients with COPD, treatment with a combination of formoterol and ipratropium is more effective than a combination of salbutamol and ipratropium: a 3-week, randomized, double-blind, within-patient, multicenter study. Chest 2001; 119: 1347-1356.
104. ZuWallack RL, Mahler DA, Reilly D, et al. Salmeterol plus theophylline combination therapy in the treatment of COPD. Chest 2001; 119: 1661-1670.
105. Gizycki MJ, Hattotuwa KL, Barnes N, Jeffery PK. Effects of fluticasone propionate on inflammatory cells in COPD: an ultrastructural examination of endobronchial biopsy tissue. Thorax 2002; 57: 799-803.
106. Culpitt SV, Maziak W, Loukidis S, Nightingale JA, Matthews JL, Barnes PJ. Effect of high dose inhaled steroid on cells, cytokines, and proteases in induced sputum in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1999; 160: 1635-1639.
107. Lung Health Study Research Group. Effect of inhaled triamcinolone on the decline in pulmonary function in chronic obstructive pulmonary disease. N Engl J Med 2000; 343: 1902-1909.
108. Pauwels RA, Lofdahl CG, Laitinen LA, et al. Long-term treatment with inhaled budesonide in persons with mild chronic obstructive pulmonary disease who continue smoking. European Respiratory Society Study on Chronic Obstructive Pulmonary Disease. N Engl J Med 1999; 340: 1948-1953.
109. Vestbo J, Sorensen T, Lange P, Brix A, Torre P, Viskum K. Long-term effect of inhaled budesonide in mild and moderate chronic obstructive pulmonary disease: a randomised controlled trial. Lancet 1999; 353: 1819-1823.
110. Burge PS, Jones PW, Spencer S, Anderson JA, Maslen TK. Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial. BMJ 2000; 320: 1297-1303.
111. Calverley P, Pauwels R, Vestbo J, et al. Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial. Lancet 2003; 361: 449-456.
112. Jones PW, Willits LR, Burge PS, Calverley PM. Disease severity and the effect of fluticasone propionate on chronic obstructive pulmonary disease exacerbations. Eur Respir J 2003; 21: 68-73.
113. Mahler DA, Wire P, Horstman D, et al. Effectiveness of fluticasone propionate and salmeterol combination delivered via the diskus device in the treatment of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2002; 166: 1084-1091.
114. Szafranski W, Cukier A, Ramirez A, et al. Efficacy and safety of budesonide/formoterol in the management of chronic obstructive pulmonary disease. Eur Respir J 2003; 21: 74-81.
115. Update of the National Heart, Lung and Blood Institute/ World Health Organization Workshop Report: Global Strategy for Asthma Management and Prevention, issued January 1995. Document no. 02-3659. Bethesda, National Institutes of Health, National Heart, Lung and Blood Institute, Global Initiative for Asthma, 2002.
116. Burrows B, Bloom JW, Traver GA, Cline MG. The course and prognosis of different forms of chronic airways obstruction in a sample from the general population. N Engl J Med 1987; 317: 1309-1314.
117. Kerstjens HA, Brand PL, Hughes MD, et al. A comparison of bronchodilator therapy with or without inhaled corticosteroid therapy for obstructive airways disease. Dutch Chronic Non-Specific Lung Disease Study Group. N Engl J Med 1992; 327: 1413-1419.
118. Walker AM, eds. Observation and Inference: an Introduction to the Methods of Epidemiology. Newton Lower Falls, Epidemiology Resources Inc., 1991.
119. Rothman KJ, Greenland S, eds. Modern Epidemiology. 2nd Edn, Hagerstown and Philadelphia, Lippincott-Raven, 1998.
120. Suissa S. Effectiveness of inhaled corticosteroids in chronic obstructive pulmonary disease: immortal time bias in observational studies. Am J Respir Crit Care Med 2003; 168: 49-53.
121. Sin DD, Tu JV. Inhaled corticosteroids and the risk of mortality and readmission in elderly patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2001; 164: 580-584.
122. Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol 1992; 45: 613-629.
123. Sin DD, Man SFP. Inhaled corticosteroids and survival in COPD: does the dose of therapy matter? Eur Respir J 2003; 21: 260-267.
124. Rochon PA, Tu JV, Anderson GM, et al. Rate of heart failure and 1-year survival for older patients receiving low-dose beta-blocker therapy after myocardial infarction. Lancet 2000; 356: 639-644.
125. Boulet LP, Becker A, Berube D, Beveridge R, Ernst P. Canada Asthma Consensus Report, 1999. Canadian Asthma Consensus Group. CMAJ 1999; 161: Suppl. 11, S1-S61.
126. Canadian Institute for Health Information. http://secure.ci-hi.ca/cihiweb/dispPage.jsp?cw.page=home_e. Accessed February 2003. Last updated April 2003.
127. National Center for Health Statistics. International Classification of Diseases Ninth Revision, Clinical Modification. 5th Edn. Los Angeles, Practice Management Information Corporation, 1999.
128. Richards J, Brown A, Homan C. The quality study of the Canadian discharge abstract database. In: Achieving Data Quality in a Statistical Agency: A Methodological Perspective. Proceedings of Statistics Canada Symposium, 2001.
129. Rawson NS, Malcolm E. Validity of the recording of ischaemic heart disease and chronic obstructive pulmonary disease in the Saskatchewan health care datafiles. Stat Med 1995; 14: 2627-2643.
130. Lacasse Y, Brooks D, Goldstein R. Trends in the epidemiology of COPD in Canada, 1980 to 1995. Chest 1999; 116: 306-313.
131. Government of Alberta. Alberta Health and Wellness. Health care coverage and services. Prescription drug coverage for seniors. http://www.health.gov.ab.ca/coverage/benefits/ seniors.html. Accessed February 2003. Last updated June 23, 2003.
132. Ontario Ministry of Health and Long-Term Care. Ontario drug benefits. http://www.gov.on.ca/health/english/program/ drugs/drugs_mn.html. Accessed February 2003. Updated daily.
133. Ministry of Industry. 1996 Census Technical Report: Mobility and Migration. Ottawa, Statistics Canada, 1999.
134. Glesby MJ, Hoover DR. Survivor treatment selection bias in observational studies: examples from the AIDS literature. Ann Intern Med 1996; 124: 999-1005.
135. General Practice Research Database. GPRD: Excellence in public health research. www.gprd.com. Accessed February 5, 2003.
136. Lawson DH, Sherman V, Hollowell J. The General Practice Research Database. Scientific and Ethical Advisory Group. QJM 1998; 91: 445-452.
137. Nazareth I, King M, Haines A, et al. Accuracy of diagnosis on general practice computer system. BMJ 1993; 307: 32-34.
138. Hansell A, Hollowell J, Nichols T, et al. Use of the General Practice Research Database (GPRD) for respiratory epidemiology: a comparison with the 4th Morbidity Survey in General Practice (MSGP4). Thorax 1999; 54: 413-419.
139. Soriano JB, Maier WC, Egger P, et al. Recent trends of physician-diagnosed COPD in women and men in the UK. Thorax 2000; 55: 789-794.
140. Soriano JB, Maier WC, Visick G, Pride NB. Validation of general practitioner-diagnosed COPD in the UK General Practice Research Database. Eur J Epidemiol 2001; 17: 1075-1080.
141. Soriano JB, Vestbo J, Pride NB, Kiri V, Maden C, Maier WC. Survival in COPD patients after regular use of fluticasone propionate and salmeterol in general practice. Eur Respir J 2002; 20: 819-825.
142. Soriano JB, Kiri V, Pride NB, Vestbo J. Inhaled corticosteroids with/without long-acting beta agonists reduce the risk of re-hospitalisation and death in COPD patients. Am J Respir Med 2003; 2: 67-74.
143. Strom BL, ed. Pharmacoepidemiology. 3rd Edn. Chichester, John Wiley & Sons, 2000.
144. The COPD Guidelines Group of the Standards of Care Committee of the British Thoracic Society. BTS guidelines for the management of chronic obstructive pulmonary disease. Thorax 1997; 52: Suppl. 5, S1-S28.
145. Kavuru M, Melamed J, Gross G, et al. Salmeterol and fluticasone propionate combined in a new powder inhalation device for the treatment of asthma: a randomized, double-blind, placebo-controlled trial. J Allergy Clin Immunol 2000; 105: 1108-1116.
146. Schols AM, Wesseling G, Kester AD, et al. Dose-dependent increased mortality risk in COPD patients treated with oral glucocorticoids. Eur Respir J 2001; 17: 337-342.
147. Hosmer DW, Lemeshow S, eds. Applied Survival Analysis: Regression Modelling of Time to Event Data. Chichester, John Wiley & Sons, 1999.
148. Jick H, Jick SS, Derby LE. Validation of information recorded on general practitioner based computerised data resources in the UK. BMJ 1991; 302: 766-768.
149. Garcia Rodriguez LA, Perez Gutthann S. Use of the UK General Practice Research Database for pharmacoepidemiology. Br J Clin Pharmacol 1998; 45: 419-425.
150. Beardon PH, McGilchrist MM, McKendrick AD, McDevitt DG, MacDonald TM. Primary non-compliance with prescribed medication in primary care. BMJ 1993; 307: 846-848.
151. Blais L, Suissa S, Boivin JF, Ernst P. First treatment with inhaled corticosteroids and the prevention of admissions to hospital for asthma. Thorax 1998; 53: 1025-1029.
152. Blais L, Ernst P, Boivin JF, Suissa S. Inhaled corticosteroids and the prevention of readmission to hospital for asthma. Am J Respir Crit Care Med 1998; 158: 126-133.
153. Bourbeau J, Ernst P, Cockroft D, Suissa S. Inhaled corticosteroids and severe acute exacerbations of chronic obstructive pulmonary disease. Eur Respir J 2003; 22: 286-289.
154. Downey W, Beck P, McNutt M, Stang M, Osei W, Nichol J. Health databases in Saskatchewan. In: Strom BL, ed. Pharmacoepidemiology. 3rd Edn. Chichester, John Wiley & Sons, 2000; pp. 325-346.
155. Bourbeau J, McIvor A. Inhaled corticosteroid should not be prescribed to all chronic obstructive pulmonary disease patients. Can Respir J 2003; 10: 148-149.
156. van der Lei J, Duisterhout J, Westerhof H, et al. The introduction of computer-based patient records in the Netherlands. Ann Intern Med 1993; 119: 1036-1041.
157. Sluiter HJ, Koeter GH, de Monchy JG, Postma DS, de Vries K, Orie NG. The Dutch Hypothesis (chronic non-specific lung disease) revisited. Eur Respir J 1991; 4: 479-489.
158. Artsennet. Artsennet, medische informatie van en voor artsen in Nederland. www.artsennet.nl. Accessed March 2003. Updated daily.
159. Vlug AE, van der Lei J, Mosseveld BM, et al. Postmarketing surveillance based on electronic patient records: the IPCI project. Methods Inf Med 1999; 38: 339-344.
160. Lamberts H, Wood M, eds. International Classification of Primary Care. Oxford. Oxford University Press, 1987.
161. de Smet P. The Dutch approach to computerized drug information: conceptual basis and realization. J Social and Admin Pharmacy 1988; 5: 49-58.
162. Cochrane AL. Effectiveness and Efficiency: Random Reflections on Health Services. London, Nuffield Provincial Hospitals Trust, 1972; pp. 20-25.
163. Sacks H, Chalmers TC, Smith H Jr. Randomized versus historical controls for clinical trials. Am J Med 1982; 72: 233-240.
164. Black N. Why we need observational studies to evaluate the effectiveness of health care. BMJ 1996; 312: 1215-1218.
165. Weinstein MC, O'Brien B, Hornberger J, et al. Principles of good practice for decision analytic modeling in health-care evaluation: report of the ISPOR Task Force on Good Research Practices-Modeling Studies. Value Health 2003; 6: 9-17.
166. Moher D, Schulz KF, Altman DA, and for the Consolidated Standards of Reporting of Trials Group. The CONSORT statement: Revised recommendations for improving the quality of reports of parallel-group randomised trials. Lancet 2001; 357: 1191-1194.
167. National Health Service Centre for Reviews and Dissemination. Undertaking Systematic Reviews of Research on Effectiveness: CRD's Guidance for Carrying Out or Commissioning Reviews. http://www.york.ac.uk/inst/crd/ crdrep.htm. CRD Report 4. 2nd Edn. 2001. Accessed March 1, 2003.
168. Waterhouse JC, Fiskwick D, Burge PS, Calverley PMA, Anderson JA, and on behalf of the Inhaled Steroids in Obstructive Lung Disease in Europe Trial Group. What caused death in the ISOLDE study? Eur Respir J 1999; 14: Suppl. 30, 387S.